Celularity Investor Relations Material
Latest events
Analyst Research & Development Day 2024
Celularity
Q4 2024
9 May, 2025
Q3 2024
5 Dec, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Celularity Inc
Access all reports
Celularity Inc. is a biotechnology company focused on developing off-the-shelf, placental-derived allogeneic cell therapies for treating cancer, immune, and infectious diseases. The company's core therapeutic products include genetically modified and unmodified natural killer (NK) cells, CAR-T cells, and mesenchymal-like adherent stromal cells. Additionally, Celularity produces placental-derived biomaterials used in various therapeutic applications. It operates through three main segments: Cell Therapy, Degenerative Disease, and BioBanking. The company is headquartered in Florham Park, New Jersey, and its shares are listed on NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
CELU
Country
🇺🇸 United States